Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Oct
05
Today In Oncology
ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Immune Cell Dysfunction Not Absence Defines Nonmelanoma Skin Cancer in Immunosuppressed Patients
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Global Gaps in Cancer-Control Expenditure Data Identified
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo